NorthWest Biotherapeutics Inc (NWBO)

[photonic5]

What’s interesting about this article is that they stated later, in 2017, that they were still waiting for OS events to accrue. In effect, the need for dilution is the prolonged survival in the trial population. Hindsight is 20/20. Linda most certainly should have diluted more diligently at $1 levels than at .20 levels. But, either way, an effective trial followed by approval will give us a product worthy of generating revenue. Probably significantly more than the $1 billion per year stated in the article.